News headlines about ANI Pharmaceuticals (NASDAQ:ANIP) have been trending somewhat positive this week, Accern Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. ANI Pharmaceuticals earned a news impact score of 0.02 on Accern’s scale. Accern also gave news stories about the specialty pharmaceutical company an impact score of 44.5979751097201 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news stories that may have effected Accern’s rankings:
- ANI Pharma (ANIP) Buys 23 ANDAs from IDT Australia, Ltd. (streetinsider.com)
- ANI Acquires 23 ANDAs from IDT Australia, Ltd. (finance.yahoo.com)
- ANI Pharmaceuticals, Inc. (ANIP) Given Consensus Recommendation of “Hold” by Analysts (americanbankingnews.com)
- ANI Pharmaceuticals (ANIP) Downgraded to “Hold” at ValuEngine (americanbankingnews.com)
- Is ANI Pharmaceuticals Inc (NASDAQ:ANIP) A Financially Sound Company? (finance.yahoo.com)
Several equities research analysts have recently weighed in on the company. ValuEngine cut ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, April 2nd. Canaccord Genuity set a $82.00 price target on ANI Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, February 27th. TheStreet cut ANI Pharmaceuticals from a “b” rating to a “c+” rating in a research note on Tuesday, February 20th. BidaskClub cut ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, February 22nd. Finally, Zacks Investment Research cut ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, January 2nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $72.25.
ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.06. The company had revenue of $47.30 million during the quarter, compared to analysts’ expectations of $52.55 million. ANI Pharmaceuticals had a positive return on equity of 23.41% and a negative net margin of 0.61%. The business’s quarterly revenue was up 23.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.84 earnings per share. research analysts predict that ANI Pharmaceuticals will post 5.17 earnings per share for the current year.
In related news, insider Arthur Przybyl sold 40,000 shares of the company’s stock in a transaction dated Wednesday, March 14th. The stock was sold at an average price of $61.83, for a total transaction of $2,473,200.00. Following the sale, the insider now owns 225,706 shares in the company, valued at approximately $13,955,401.98. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP James G. Marken sold 4,177 shares of the company’s stock in a transaction dated Monday, March 5th. The shares were sold at an average price of $61.92, for a total value of $258,639.84. Following the sale, the senior vice president now owns 66,439 shares in the company, valued at approximately $4,113,902.88. The disclosure for this sale can be found here. In the last three months, insiders sold 187,620 shares of company stock valued at $11,696,748. Insiders own 31.80% of the company’s stock.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.